Considering the potential use of CHEK2 inhibitors for primordial oocyte protection, more information is needed regarding CHEK2 activation and its downstream effectors in chemotherapy-induced POI to identify cancer treatments that could benefit from oocyte-protective activity of CHEK2 inhibitors. Here, CHEK2 is linked to cancer.